Ropes & Gray advised Verastem Oncology in a collaboration to evaluate Mirati Therapeutics’ investigational KRAS inhibitor drug with Verastem’s investigational inhibitor drug in combination for mutant non-small cell lung cancer. The transaction was announced on November 22.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and life sciences associate Amanda White (both of Boston).
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.